Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

3 Customer Reviews

  • Immunofluorescence staining of LC3 protein expression of U2OS cells treated with DMSO (negative control), Rap (positive control, 500 nM), Tha (1 μM), Tun (2 μg/mL), BFA (10 μg/mL), and DTT (4 mM) for 8 h. Immunoblot of ER-phagy-related proteins of U2OS cells treated with four ER stress inducers.

    Nanoscale, 2018, 10(18):8796-8805. Brefeldin A purchased from Selleck.

    Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

  • CSFV proliferation in ST cells with or without BFA was observed by IFA at 24, 48 and 72 hpi.

    J Biosci, 2018, 42(1):43-56. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NWO3fFl6TnWwY4Tpc44hSXO|YYm= Mm\yNkDPxE1? MXmxJIg> NFz1bnhqdmirYnn0d{B1cGViTD3EU3BCKCh{MNMg{txOMS2rbnT1Z4VlKHS{YX7zbYVvfCCHUluxM|IheGixc4Doc5J6dGG2aX;uxsA> MkjKNlY{PjNzOUG=
C2C12 NUH5[mhTTnWwY4Tpc44hSXO|YYm= NG\QUHYyyqEQvHevcYw> NEPYSJAyyqCq NIPDUWti[m:uaYPo[ZMh[3m2b3vpcoUhemWuZXHz[UBnem:vIFOyR|EzKG27b4T1ZoV{ NVXjSpJHOjZ{OUGyO|k>
MEFs WT M3;SRWZ2dmO2aX;uJGF{e2G7 NYj2V|dbPcLizszN MWqyNEBucW5? MlPZZ4F2e2W|IILld4ll\W62IHXufplu\XNic4XjbEBieyCQQVfUMWdHWCxidH:g[Iln\nW|ZTDiZYNsKHSxIITo[UBGWg>? MnOyNlYyQTZyMkO=
MEFs VAMP7 KO M4nPdGZ2dmO2aX;uJGF{e2G7 NYfYcGpiPcLizszN M3;hZVIxKG2rbh?= MVjjZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT MWqyOlE6PjB{Mx?=
SMCs M3fyZmZ2dmO2aX;uJGF{e2G7 MX2xNOKhyrWpL33s NX7HcnM5OC1zMjDo NYf1UpVyTE2VTx?= Ml;zd4hwf3NiYTD0doVv\CC2b4fhdoR{KGFiaHnnbIVzKGOxbnPlcpRz[XSrb36gc4YhfGinIFXSM3NTKG6ndIfvdoshcW5idHjlJJBmemmwdXPs[YFzKGG{ZXJCpC=> MX2yOlE4OjB6MB?=
SMCs M1u4[2Z2dmO2aX;uJGF{e2G7 MVGxNOKhyrWpL33s MmHZNE0yOiCq NV7wR|Y{TE2VTx?= NVzXcpVm[2G3c3XzJIEhfHKjboPp[Y51KEOjMjxCpJJmdGWjc3Wg[pJwdSC2aHWgSXIwW1MEoB?= NWTWV2l{OjZzN{KwPFA>
HEMC-1 MWjGeY5kfGmxbjDBd5NigQ>? MYKwMlHDqML3Zz;tcC=> MkPsNlTDqGh? NWD3UHZ[[2G3c3XzJIEhcGmpaHXyJIlvcGmkaYTvdpkh\W[oZXP0JI9vKGW6b3P5eI9{cXNidHjhckBvd2OxZHH6c4xm M{PGW|I2QTd{N{W5
HUVEC M2fxT2Z2dmO2aX;uJGF{e2G7 M1vndVExyqEQvF2= MlriNeKhcA>? MXHEUXNQ MYLhZo9tcXOqZYOgbJlxd3irYT3pcoR2[2WmIILlcIVie2Vib3[gRXRRKG[{b32gZZBq[2GuIHHu[EBj[XOxbHH0[ZJidCC|dYLmZYNmew>? NYraN|RQOjV7NU[5PFg>
HUVEC MUjGeY5kfGmxbjDBd5NigQ>? M1Pq[FExyqEQvF2= MWixxsBp NGnycYNFVVOR MXvpcoNz\WG|ZYRCpJRp\SCwdX3i[ZIh[W6mIHnueIVve2m2eTDv[kBndHWxcnXzZ4VvfCCjcnXhd{Bme3CnY3nhcIx6KGmwIIDldolvfWOuZXHyJJNx[WOn MYmyOVk2Pjl6OB?=
Caco-2 MoDYSpVv[3Srb36gRZN{[Xl? NWXkclJOOi53IN88US=> NXH5fFA5OzBibXnu M{PXcoF1fGWwdXH0[ZMhfGinIGTHSk3PujFvbXXkbYF1\WRiaX7jdoVie2ViaX6gV2VTXCCodX7jeIlwdg>? MV:yOVk2PDl|MR?=
NRK NYLxPI17TnWwY4Tpc44hSXO|YYm= MnjzNlAx6oDHbnevcYw> NW\OeWFNPOLChXi= NISxOnpFVVOR MV3y[ZNkfWW|IH3peI91cWNicILv[5Jme3Orb36= MnfTNlU6PDh3OE[=
HeLa NHmzNFZHfW6ldHnvckBCe3OjeR?= NIHD[IgzODEkgJXu[{9udA>? NGLSOpM{KGh? NX3ESZltTE2VTx?= MUjpcoR2[2W|IITo[UBienSrZnnjbYFtKGK{ZXHrMZVxKG:oIITo[UBId2ypaTDjc41xdGW6 MYGyOVk1QDV6Nh?=
COS MmXTSpVv[3Srb36gRZN{[Xl? NHvoXIsyKM7:Zz;tcC=> NWDpUWI5OyCq NEj2ZY1kd22ybHX0[Yx6KGSrc4DldpNmeyC2aHWgRXAuOSC|aXfuZYzDqA>? NF30U3ozPTlzNUmwNC=>
DF1  MULGeY5kfGmxbjDBd5NigQ>? NILjOnEyyqEQvF5CpC=> NXfNSmV4PDhiaB?= NEnYc2NFVVOR NFzSWWtlcXOyZYLz[ZPDqHSqZTDlfI9o\W6xdYOgR3NI[WyQQXPUNkBxem:2ZXnu NV\NV5k5OjV6MEewOVQ>
nHDFs  NVTUN4F[TnWwY4Tpc44hSXO|YYm= M2\P[|HDqM7:TdMg M3HERVLDqGh? NHTLN3BxemW4ZX70d{B1cGViYYPz[Y1jdHlib3[gZ5l1d3OxbHnjJINw[XRicILveIVqdnNib370c{BId2ypaTDt[Y1jemGwZYO= NGnsXo8zPTd5Mk[xOi=>
FRT  MmrZSpVv[3Srb36gRZN{[Xl? MoL1OUDPxGdxbXy= NIj1doozyqCq MVjicI9kc3NidILh[oZq[2urbnegeIhzd3WpaDD0bIUhT2:uZ3mgZ49ueGyneDDifUBqdmirYnn0bY5oKEWULYTvMWdwdGerIITyZY5{eG:{dB?= NV:5WYViOjV5NkexNVU>
FRT  NUDLc5pCTnWwY4Tpc44hSXO|YYm= NUSxZolMPSEQvHevcYw> NH3nTIkzyqCq M3zT[5Bz\X[nboTzJJRp\SCrbnPy[YF{\SCrbjDjcIVifmWmIN8xJJN2[nWwaYTzJJdp\W5iW17hL31qyqC5YYOgdoVlfWOnZB?= NX\NR2VrOjV5NkexNVU>
HepG2  MV;GeY5kfGmxbjDBd5NigQ>? MYix5qCKyrWPwrC= MVeyOEBp NYnpWJRrTE2VTx?= M3fRNYRm[3KnYYPld{B1cGVibHX2[Ywhd2ZiUGjSJI1TVkF? MUOyOVYyPjV7Nx?=
SMCs NIDCNFRHfW6ldHnvckBCe3OjeR?= NWjsPY1EOc7:Zz;tUC=> MVOzJIg> MVXhZ4N2dXWuYYTld{BEVlC\MjDwdo91\WmwIHnuJJRp\SCHUjDjc41x[XK2bXXueEBidmRibn:gcI9v\2W{IHPvMYxw[2GuaYrl[EB4cXSqIITo[UBId2ypaTDtZZJs\XMEoB?= MU[yOVU5QTR{NR?=
OB-6 NXTMNVIySXCxcITvd4l{KEG|c3H5 NYPIR2JzOi55wrFOwG0> MnXUOFghcA>? NWfncXB7cW6mdXPld{BieG:ydH;zbZM> MXiyOVU{OjR6MB?=
iPSC-CMs  MVTGeY5kfGmxbjDBd5NigQ>? NF;YNZQ2ODBibnevcYw> M4ewNlQ5KGh? M1PoOolv[3KnYYPld{B1cGViaX70[Y5{cXS7IH;mJJRp\SCqaXfo[ZIhdW:kaXzpeJkhVEGPUIOgZZQhfGinIHPvd5Qhd2ZidHjlJIxwf2W{IH3vZoltcXS7IIPw[YNq\XN? M2nOflI2PDh6Nk[2
SP-Nluc NIKxfWpHfW6ldHnvckBCe3OjeR?= NHLxbYQ2KG2pL33M NHe1b2c3KGh? NE\hUWhFVVORwrC= NIrxT4Nk[XW|ZYOgZY4hcW6lcnXhd4UhcW5icnXwc5J1\XJiYXP0bZZqfHliaX6geIhmKHCjcnHzbZRm NV\wV|ZGOjV|OUK5PVg>
PEXEL-Nluc MWLGeY5kfGmxbjDBd5NigQ>? Mn7oOUBu\y:vTB?= NYL3Zm5ZPiCq NG\0NHhFVVORwrC= NVjI[Jl{[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? MXqyOVM6Ojl7OB?=
H1299 MXrGeY5kfGmxbjDBd5NigQ>? M{nFelExKM7:Zz;tcC=> NXP6U3U{OjRiaB?= NYe3SJZJcW6mdXPld{BifXSxcHjh[5nDqA>? MnnUNlU{QDh7N{C=
MDA-MB-231 M33OOmNmdGxiVnnhZoltcXS7IFHzd4F6 MV6w5qCUPTBizsznM41N NFPTNW41QCCq NWXMbWZ1TUN3MNMgQUAxNjBzNjFCuYcwdUx? NIXDPXczPTN3NkW2Oy=>
MDA-MB-231 NEjOOFZCeG:ydH;zbZMhSXO|YYm= MXmwMlEh|rypL33M M3\zfFQhcA>? M{jmeolv\HWlZYOgZZBweHSxc3nz NIO5ZnAzPTN3NkW2Oy=>
MDA-MB-231 NHvDbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrrdXoxNjBzL{CuNFUh|rypL33M M3u5RlI1KGh? NWTEbVF4cW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kB{fWJvR{GgZ4VtdCCmZXLybZM> MknWNlU{PTZ3Nke=
MDA-MB-231 NH;pbVRCeG:ydH;zbZMhSXO|YYm= NXzBdGp7OC5yNfMAl|Eh|rypL33M NGn6VHkzPCCq NW\BUmZzcW6mdXPld{BRSVKSIDjwc4x6KEGGUD3ybYJwe2VicH;sfY1memG|ZT2xLUBkdGWjdnHn[S=> NF24W2kzPTN3NkW2Oy=>
MDA-MB-231 Mn3xSpVv[3Srb36gRZN{[Xl? MlrxNQKBmzVyIN88[{9uVA>? M2Toe|I1KGh? M2L0eIlvcGmkaYTzJJRp\SCob4LtZZRqd25ib3[gN2Qh[W6mIELEJINwdG:waXXz NEHybZIzPTN3NkW2Oy=>
A172 NV7FZYxJTnWwY4Tpc44hSXO|YYm= NUnJWYlSOTEEoN88[{9udA>? MVK0xsBp M2DlRmROW00EoB?= NXrie4F6emW|dXz0d{BqdiC2aHWgdoV1em:pcnHk[UB1emGwc4DvdpQhd2ZiZnz1c5Jme2OnboSg[5JidnWuZYO= M2[0TlI2OjN7NUC3
KMS-6 MYTGeY5kfGmxbjDBd5NigQ>? MXyxxsDPxE4EoB?= MXWyOEBp NGnncWtmgGirYnn0d{Bp[WyoIITo[UB{\WO{ZYTpc44hd2ZiZ3HsZY5qdi2OSTDhd{BlcWRidHjlJINwdnS{b3y= MX:yOVIzQTF{Nh?=
MEC Mn65SpVv[3Srb36gRZN{[Xl? NXjXVm12OSEQvF2= MnrzNU42KGh? M3rWWoNifXOnczDhJIRz[W2jdHnjJIRm[3KnYYPlJIlvKHSqZTDzeZJn[WOnIG\FS2ZTOg>? NVy4W2c6OjV{Mki4NVU>
HEK293/hERG MmTRSpVv[3Srb36gRZN{[Xl? MXWxNOKh|ryP M3\ZblHDqGh? M1XUSpJme3WudIOgbY4h[SC2aX3lMYRmeGWwZHXueEBz\WS3Y4Tpc44hdWG2dYLlJIhGWkdicILveIVqdsLi NWjzZ4VJOjV{MUi0Olk>
RBE4 MX3BdI9xfG:|aYOgRZN{[Xl? NG\iWnYzyqEQvF2= MlzxN-KBmzJ2wrDo M1f3ZYlv\HWlZYOgZZBweHSxc3nzJJRqdWViZHXw[Y5l\W62bIm= M3rNbFI2OTJ6MEK1
RBE4 NVzvRpBYTnWwY4Tpc44hSXO|YYm= NFfacGUzyqEQvF2= MnexN-KBmzJ2wrDo M1;jfYlv[3KnYYPld{B1cGViWFLQNUBxem:2ZXnuJIxmfmWuczDh[pRmeiB|IHHu[EA3yqCqIH;mJJRz\WG2bXXueC=> M13GR|I2OTJ6MEK1
RBE4 NYfj[IhnTnWwY4Tpc44hSXO|YYm= NVu5b4NEOsLizszN M1PuWlPjiJN{NNMgbC=> NHvxdYRqdmO{ZXHz[ZMh[WO2aY\lJINie3Cjc3WtNVIhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>? MYSyOVEzQDB{NR?=
RBE4 MVrGeY5kfGmxbjDBd5NigQ>? MVWyxsDPxE1? NF33XZY{6oDVMkVCpIg> NHLPTVlqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDSU3MhfGmvZT3k[ZBmdmSnboTsfS=> NIPqXHYzPTF{OECyOS=>
RBE4 NILz[GtHfW6ldHnvckBCe3OjeR?= M1jhNlLDqM7:TR?= MkL5N-KBmzJ2wrDo NGG4O29qdmS3Y3XzJIEh\GWuYYnl[EBl\XCuZYTpc44hd2ZidHjlJGVTKEOjMjxCpINwdnSnboSgZZQhPsLiaDDv[kBqdmO3YnH0bY9vKHOrZ37p[olk[W62bIm= MoLhNlUyOjhyMkW=
RBE4 NFu1bIhHfW6ldHnvckBCe3OjeR?= M{PYNFLDqM7:TR?= MXqz5qCUOjUEoHi= M3zjfolv\HWlZYOgZY4hd3[ncnzvZYQhd2ZiQ3GyL:KhcW5idHjlJI1qfG:laH;u[JJq[SCrbjD0bIUh\mm{c4SgOuKhcCCxZjDpcoN2[mG2aX;uJEhx6oDLPPMAjVAvODBzKTDieZQhS2F{K9MgcIV3\Wy|IHnuJJRpcXNib4LnZY5mdGynIHTlZ5Jm[XOnZDDh[pRmeiBzMtMgbEBw\iCrbnP1ZoF1cW:w M1vsb|I2OTJ6MEK1
Huh-7  MUnGeY5kfGmxbjDBd5NigQ>? NGT1[pEy|rypL33M Mn7UN-KBmzJ2wrDo NV;Be2tscW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDBVGUyKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz NHv6PWUzPTB{NkG3OC=>
HepG2  NE\PV4dHfW6ldHnvckBCe3OjeR?= MU[x{txoN22O NXzuPWNjO+LCk{K0xsBp MWDpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NV3UTJdzOjVyMk[xO|Q>
H838-LKB1 NXfJ[Fd[TnWwY4Tpc44hSXO|YYm= M1m3cFMxyqCwZz;tcC=> NXS1c5huOTJxMUigbC=> NV;6V3lKcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? NGLaVJgzPTBzMUC4Ni=>
H838-KDLKB1  NHi4emdHfW6ldHnvckBCe3OjeR?= MnnTN|DDqG6pL33s MmG5NVIwOThiaB?= MnzNbY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> NGjMVHgzPTBzMUC4Ni=>
H838-KDLKB1  NGrsdnpHfW6ldHnvckBCe3OjeR?= M2DTUlMxyqCwZz;tcC=> NXfzTnFXOTJxMUigbC=> MYjpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyaH;zdIhwenmuYYTl[EBmUUZ{zsGgLJBpd3OyaH:t[WlHOs7zKR?= MWCyOVAyOTB6Mh?=
3T3-L1 NWrLfY9QTnWwY4Tpc44hSXO|YYm= M{\BOVUh|rypL33s M1HzSFMxKG2rbh?= MWHtbY1q[3NidHjlJIVn\mWldIOgc4YhcW6|dXzpckBidmRiY3H1d4V{KHKxYoXzeEBxcG:|cHjvdplt[XSrb36gc4YhSWu2IDjT[ZIhPDd|KTDhcoQheGixc4Doc5J6dGG2aX;uJI9nKEGVMU[wJEhVcHJiNkSyJIFv\CCVZYKgOVg5MQ>? NUP4VGN7OjR6NEO4Nlc>
3T3-L1 NHLybJRHfW6ldHnvckBCe3OjeR?= MkDjOUDPxGdxbXy= NWLpZYFLOzBibXnu MkT3doVk[XCrdIXsZZRmeyCrboP1cIlvKGGldHnvckB4cXSqIILld5Bm[3RidH:gdoVofWyjdHnu[{BCc3RiYXP0bZZqfHliYX7kJGFUOTZyIIDoc5NxcG:{eXzheIlwdg>? MmHZNlQ5PDN6Mke=
3T3-L1 NI\DOlhHfW6ldHnvckBCe3OjeR?= NV7YTYh[PSEQvHevcYw> NFq0SXk{OCCvaX6= NUnnOVI4[2G3c3XzJJJmfmW{c3nicIUhemWmaYP0doljfXSrb36gc4YhT0yXVES= NWTWPVZTOjR6NEO4Nlc>
3T3-L1 NGTZ[4RHfW6ldHnvckBCe3OjeR?= NXjUfnN[PSEQvHevcYw> M1TOcVHDqGh? MXjjZZV{\XNicnXkbZN1emmkdYTpc44hd2ZiR1zVWFQh[nW2IH7veEBqdmO{ZXHz[UBqdiCpbIXjc5NmKHWydHHr[S=> NFfs[3ozPDh2M{iyOy=>
3T3-L1 NV[5NVdjTnWwY4Tpc44hSXO|YYm= MXm1JO69\y:vbB?= M{\JZVHDqGh? MV\jZZV{\XNicHjvd5Bpd3K7bHH0bY9vKG:oIITo[UBHd3iRMTD0doFve2O{aYD0bY9vKG[jY4Tvdi=> NVfaN3VPOjR6NEO4Nlc>
HeLa  M4XKTWZ2dmO2aX;uJGF{e2G7 MWm1JO69\y:vbB?= MXqzJIg> MVfjZZV{\XNiboXjcIVieiCneHPseZNqd25ib3[geIhmKE[xeF:xJJRz[W6|Y4LpdJRqd25iZnHjeI9zKGGwZDDk[YNz\WG|ZYOgeJJidnOlcnnweIlwdiCxZjDGc5hQOS2{ZXf1cIF1\WRiZ3Xu[ZM> NUH6b3VwOjR6NEO4Nlc>
HEK293 MVXGeY5kfGmxbjDBd5NigQ>? MWC1xsDPxGdxbXy= NGjkW5YyOsLiaB?= Mn\wZYJwdGm|aHXzJGNOSS2rbnT1Z4VlKEOURVzENkB{\WO{ZYTpc44> NEK5co8zPDZ6N{SzNS=>
COS-1 MWDGeY5kfGmxbjDBd5NigQ>? MmrWOUDDvWdxbXy= NVnSZYdlOjRiaNMg MU\y[ZN1emmldIOgcI9k[WyrenH0bY9vKG:oIF7CJIlvKHSqZTDw[ZJqdnWlbHXhdkBz\Werb39CpC=> MkjwNlQ3PzF5NUG=
PRP MWfGeY5kfGmxbjDBd5NigQ>? NHv5eVMyOCEQvF2= MlTnZYJzd2ejdHXzJHNFTi1zzsGtcYVlcWG2ZXSgR3hEWjdiZYj0[ZJv[WyrenH0bY9vyqB? NEKwNnczPDZ4OEe1NC=>
RAW264.7 MlzIRZBweHSxc3nzJGF{e2G7 MWi0JO69VQ>? NIG2VJg1QCCq M1PPW4F1fGWwdXH0[ZMhfGinIHnubIljcXSrb36gc4Yhd3hvTFTMMYlv\HWlZXSgZZBweHSxc3nzJIFv\CC2aHWg[oFkcWyrdHH0bY9vKG:oIHPoc4xme3Sncn;sJIVn\my3eDDifUBC[y2qRT2xPGEuVkh{ NX;RcJoxOjR4M{mwN|I>
MDMs NHLIfIlCeG:ydH;zbZMhSXO|YYm= M4Swc|Ex6oDLzsznM41t NIfxRmQyOi9zNTDo NGC3UXVqdmS3Y3XzJIFxd3C2b4Ppdy=> MojMNlQ2PTZ4OUW=
PMHs  M4HSVmZ2dmO2aX;uJGF{e2G7 NWT6ZpNwOTEkgKOyNQKBkc7:Zz;tcC=> MkK1NlTjiImq NV\odm9JTE2VTx?= NIm1T4FqdmS3Y3XkJGVTKHO2cnXzdy=> M1;ZRlI1PDB5MkSy
PMHs  MlvORZBweHSxc3nzJGF{e2G7 MUexNQKBmzJy4pEJ{txoN22u MonpNlTjiImq MXfEUXNQ NVOzcZl3cW6lcnXhd4V{KGOnbHyg[IVifGh? M3PPZlI1PDB5MkSy
HEK293/tau MofNSpVv[3Srb36gRZN{[Xl? NXToR3FoPSEQvF2= NG\mbYcyNzJxNDDo MoG3bY5lfWOnczDHc4xocSCocnHncYVvfGG2aX;uxsA> M4j0eVI1OzZ6MEi5
HEK293/tau NHfCVI5HfW6ldHnvckBCe3OjeR?= MoLtOUDPxE1? M1TlTVMhcA>? MmTCbY5lfWOnczD0ZZUhcHmyZYLwbI9{eGixconsZZRqd25? MVKyOFM3QDB6OR?=
ADF MUDGeY5kfGmxbjDBd5NigQ>? NIHhNI8yOCEQvF2= NH3VcooyPiCq MoPMbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> NVjKcIN6OjR{MkiyN|I>
U373  MXfGeY5kfGmxbjDBd5NigQ>? M1XNOlExKM7:TR?= NVPhSYxHOTZiaB?= NGDTRYdqdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? NIjTdIkzPDJ{OEKzNi=>
RKO-HIPK2i NIPVc4JHfW6ldHnvckBCe3OjeR?= M2DRSVExKM7:TR?= Mn;2NVYhcA>? MWTpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> MlfENlQzOjh{M{K=
ADF  MkHOSpVv[3Srb36gRZN{[Xl? NVy4fFRXOTBizszNxsA> MVS2JIg> MUTpcZBicXK|IITo[UBFSyCjY4TpeoF1cW:w NWPDe3RWOjR{MkiyN|I>
Huh7 MkXSSpVv[3Srb36gRZN{[Xl? MmTzOUDPxGdxbXy= MlrROEBp MVHhZo9tcXOqZYOgeIhmKHOnY4LleIlwdiCxZjCgbY51emGlZXzseYxieiCDcH;C NWe4b|J7OjRzMECxOFA>
Huh7 MWLGeY5kfGmxbjDBd5NigQ>? NHHpbmw2KM7:Zz;tcC=> MUexJIg> MVXjZZV{\XNiYTDzbYdvcW[rY3HueEBqdmO{ZXHz[UBqdiCDcH;CMYNz\XOlZX70dy=> NF61dG0zPDFyMEG0NC=>
Huh7 NW\Tb5R1TnWwY4Tpc44hSXO|YYm= MXO15qCUOTEEoH7nM41t M1vSXFEzKGh? NFnW[|FqdmO{ZXHz[ZMhSXCxQj3jdoV{[2WwdIOge4l1cG:3dDDpcohq[mm2aX7nJJNm[3KndHnvci=> NVrsSJJzOjRzMECxOFA>
BAECs M3n2bmZ2dmO2aX;uJGF{e2G7 M4LiUFUh|rypL33s NGr3NYcxNTRiaB?= MnfHbY5lfWOnczD0bIUhemGyaXSg[IVxcG:|cHjvdplt[XSrb36gc4Yh\U6RUzDheEBU\XJzMUe5 NUKxUo1DOjRyOEWyNlU>
Macrophages NH3EdFVHfW6ldHnvckBCe3OjeR?= MmDUO|EhyrWP MkPnOkBp NHP2S49qdmirYnn0d{BtfW6jc3nuJIlvfGW{bnHsbZpifGmxbtMg M4TmOFI1ODN7N{Sw
Colo 205 MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjBRYUxNTVizsznM41N NHy1VVM1QCCq MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiC|dYPw[Y5{cW:wIHP1cJR2emW|IIfpeIgh[W5iZYP0bY1ifGWmIFnDOVAhd2ZifkG1JI5oN22O NH3JRlEzOzl5M{m5Oi=>
Colo 205 NEKxWplHfW6ldHnvckBCe3OjeR?= MUmwMlAyOi1yLkCyOUDPxGdxbVy= NE\2dIUyPCCm NYnUVm8yemWmdXPld{B1cGViY3zvco9o\W6rY3n0fUBw\iCFb3zvJFIxPSCFU1Pz M{nwOVI{QTd|OUm2
Colo 205 NXTzOGk3SXCxcITvd4l{KEG|c3H5 MnHzNE4yKM7:Zz;tUC=> NEXrN5ExNTJ2IHi= MVXpcoR2[2W|IHHwc5B1d3OrczDv[kBEd2yxIEKwOUBk\WyuczDpckB{fXOyZX7zbY9vKGO3bIT1doV{ M3XaOlI{QTd|OUm2
Colo 205 MYHGeY5kfGmxbjDBd5NigQ>? M2LDZ|AvODF3IN88[{9uVA>? NX:4S5pPOjRiaB?= NWXzbo1vcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBGWiC|dILld5MuemWuYYTl[EBo\W6ncx?= MlfaNlM6PzN7OU[=
Colo 205 NF3kSJNHfW6ldHnvckBCe3OjeR?= NUjTNWZ2OC5yMUWg{txoN22O MYWyOEBp MnLqbY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIF3NVJM> NFzTSJozOzl5M{m5Oi=>
IBRS2 NEKxTGlHfW6ldHnvckBCe3OjeR?= M3HqPFUh|rypL33s NV3UVFExOC53IHi= M3;SWWROW09? NIW0ZnNlcXO{dYD0d{B1cGViRWLHTWMh[W6mIFfvcIdqyqB? MXGyN|k3OzV|NB?=
IBRS2 NGHPVIJHfW6ldHnvckBCe3OjeR?= NEO1T5k2KM7:Zz;tcC=> MXuwMlUhcA>? MYnEUXNQ M{HY[4VvcGGwY3XzJGZOTFZiaX7m[YN1cW:w NFfuOWczOzl4M{WzOC=>
HeLa MX3GeY5kfGmxbjDBd5NigQ>? NFrNVYgzKM7:TR?= M{[wXVIhcMLi NYTvbnc3[XS2ZX71ZZRmeyC2aHWgWG5HNWmwZIXj[YQhe2WlcnX0bY9vKG:oIFnMMVE2 NVm0emtDOjN7NUC4PVI>
HFS  NIL1eJZHfW6ldHnvckBCe3OjeR?= MUiwMVEh|rypL33s MkHJNlQhcA>? NGPlOWZIVFSSIHX4dJJme3Orb36gdoVi[2inczDhJJBt[XSnYYWgZZQh[2:wY3XueJJifGmxboOgZZMhdG:5IHHzJFAvODFiwsXnM41t NHXpVG8zOzh7NE[zNy=>
HFS  NYT5S5ROTnWwY4Tpc44hSXO|YYm= NX\OS4xvOC5yMTFCuYcwdWx? MUSyOEBp MmLmbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIdtgWOxc4DobY5od2yrcHnkJJN6dnSqYYPlJIdmdmW|IHH0JFYhcA>? NHvrNZUzOzh7NE[zNy=>
OVCAR-3 MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv6NnEy6oDVMUZCpO69VcLi MYKyOOKhcA>? Moj5bY5lfWOnczDhJIxwe3Nib3[gZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgcLi NUTtN|E4OjN6Mk[5OlQ>
OVCAR-3 NIfWOFdHfW6ldHnvckBCe3OjeR?= NF3oOWUy6oDVMUZCpO69VcLi NUTROZFXOjUEoHi= NFz2NlBqdmS3Y3XzJI52[2ynYYKg[IFu[Wen MV2yN|gzPjl4NB?=
OVCAR-3 MmCxRZBweHSxc3nzJGF{e2G7 MYOxMVExyqEQvF2= MYC0JIg> MnjMbY5lfWOnczD0bIUh[WO2aY\heIlwdiCxZjDhdI9xfG:|aYOtdoVt[XSnZDDwdo91\Wmwcx?= MYOyN|gzPjl4NB?=
OVCAR-3 MYrBdI9xfG:|aYOgRZN{[Xl? MWGxNOKh|ryP MXWyOOKhcA>? NVT4eYNtcW6mdXPld{Bi[3SrdnH0bY9vKG:oIHPhd5Bie2W| NX3QSZpDOjN6Mk[5OlQ>
OVCAR-3 MVTGeY5kfGmxbjDBd5NigQ>? NWXxbVF4OeLCk{GwxsDPxE1? M2nJdFI1yqCq NIfMXHNqdmS3Y3XzJIRqe3K3cITpc44hd2ZidHjlJI1qfG:laH;u[JJq[WxidILhcpNu\W2kcnHu[UBxd3SnboTpZYw> M2XPXlI{QDJ4OU[0
OVCAR-3 MUHGeY5kfGmxbjDBd5NigQ>? NHXUdWoy6oDVMUFCpO69VQ>? NFrxS4szPMLiaB?= NXnSc5ZXcW6mdXPld{Bnd3KvYYTpc44hd2ZicnXhZ5RqfmVib4j5[4VvKHOyZXPp[ZM> M{fudVI{QDJ4OU[0
OVCAR-3 NYPiTphHTnWwY4Tpc44hSXO|YYm= NEj0eFEy6oDVMUFCpO69VQ>? MnvYNlTDqGh? NUOzcYl[cW6qaXLpeJMh[2WubDDh[Ihme2mxbjDhcoQhdWmpcnH0bY9v NGPXO3AzOzh{Nkm2OC=>
MKN45 M4T2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrMTWM2ODxyLkCwNUDPxGdxbXy= M1mwUVI{Pzl|M{Sy
LOVO MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMUKg{txoN22u Mn3qNlM4QTN|NEK=
A549 NFm5UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP4cZE3UUN3ME2wMlA1KM7:Zz;tcC=> NFzy[pMzOzd7M{O0Ni=>
MDA-MB-435 M4LSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjsNGdKSzVyPECuNFAyKM7:Zz;tcC=> Mn7rNlM4QTN|NEK=
HepG2 M4THN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGWzeGVKSzVyPECuNFAyKM7:Zz;tcC=> NG\hNXAzOzd7M{O0Ni=>
HL-60 NFnt[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL0NXU5UUN3MEywMlAxOSEQvHevcYw> NV\L[VNHOjN5OUOzOFI>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:

[5]

+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products0

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID